Tadalafil and sildenafil are selective inhibitors of phosphodiesterase type 5, showing marked pharmacokinetic variability in patients with pulmonary arterial hypertension. It has been reported that sildenafil is a substrate for P-glycoprotein (P-gp), but whether tadalafil is a substrate for P-gp remains to be determined. The objective of the present study was to elucidate whether tadalafil is a substrate for P-gp. Transcellular transport of sildenafil and tadalafil (5 µM each) was examined using renal epithelial LLC-PK 1 and P-gpexpressing LLC-GA5-COL150 cell monolayers. The efflux ratio of the basal to apical (B to A) transport of sildenafil to the A to B transport after 120-min incubation in LLC-GA5-COL150 cells (1.52) was significantly higher than that in LLC-PK 1 cells (0.711). The efflux ratio of the B to A transport of tadalafil to the A to B transport after 120-min incubation in LLC-GA5-COL150 cells (10.4) was significantly higher than that in LLC-PK 1 cells (1.23). In LLC-GA5-COL150 cell monolayers, the V max and K m values of sildenafil transport calculated from a modified Michaelis-Menten equation were 101 64 pmol/min/cm 2 and 112 47 µM, respectively. On the other hand, those of tadalafil transport were 13.6 4.8 pmol/min/cm 2 and 22.7 9.3 µM, respectively. In the presence of a P-gp inhibitor (PSC833), the B to A transport of tadalafil was decreased by 28.6% in LLC-GA5-COL150 cells, and the A to B transport of tadalafil was 6.59-fold greater than that in its absence. These results indicate that tadalafil is a substrate for P-gp.Key words tadalafil; sildenafil; P-glycoprotein Tadalafil and sildenafil are potent and selective inhibitors of cyclic GMP-specific phosphodiesterase type 5 (PDE5) in vascular smooth muscle.1) These drugs have been used as treatments not only for erectile dysfunction, but also for pulmonary arterial hypertension (PAH).2) Sildenafil has a short half-life of about 3-5 h, 3) whereas tadalafil has a long half-life of about 17.5 h.4) Due to its long half-life, tadalafil has the advantage of once-a-day dosing compared with 3-times-a-day dosing for sildenafil. 5) For patient convenience and compliance, the transition from sildenafil to tadalafil has been tried in stable patients with PAH. 5) However, it is necessary to understand the difference between the pharmacokinetics of the two drugs for their safe use.Sildenafil is eliminated predominantly by hepatic metabolism and converted to an active metabolite, N-desmethyl sildenafil.6) In healthy men, metabolites are predominantly excreted into the feces (73-83%) and to a lesser extent urine (6-15%) after an oral dose.6) In our previous study, we confirmed that the N-demethylation of sildenafil was mediated by both CYP3A4 and CYP3A5 isoforms. 7) That is, the Michaelis-Menten constant (K m ) values for CYP3A4 and CYP3A5 isoforms were estimated to be 27.7±7.5 and 17.4±3.2 µM, respectively, and the maximum transport rate (V max ) values were 30.7±11.3 and 18.9±6.1 pmol/min/pmol P450, respectively.7) In addition, Choi and Song 8)reported that s...